Duloxetine (Cymbalta) Scheduling Status
Duloxetine (Cymbalta) is not a scheduled medication under the Controlled Substances Act. It is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) used for treating various conditions including neuropathic pain, depression, and anxiety disorders 1.
Classification and Regulatory Status
- Duloxetine is an SSNRI antidepressant medication that does not appear in any of the five controlled substance schedules (I-V) 1
- It is approved by the FDA for multiple indications including diabetic peripheral neuropathy, major depressive disorder, generalized anxiety disorder, and fibromyalgia 2, 3
- Unlike opioid medications (such as tramadol) which are scheduled due to abuse potential, duloxetine does not have significant abuse liability 1
Clinical Applications
- Duloxetine is commonly prescribed as a first-line treatment for:
Prescribing Considerations
- Typical starting dose is 30 mg once daily for one week, then increased to 60 mg once daily 1, 5
- Maximum recommended dose is 60 mg twice daily (120 mg/day) 1, 3
- No special prescription forms or DEA number are required to prescribe duloxetine, unlike scheduled medications 5
- Duloxetine should be tapered when discontinuing to prevent withdrawal symptoms, especially after treatment longer than 3 weeks 1, 3
Safety Profile and Precautions
Common adverse effects include nausea, dry mouth, headache, constipation, dizziness, and fatigue 1, 3
Serious but rare adverse effects may include:
Duloxetine may interact with drugs metabolized by CYP1A2 and CYP2D6 1, 3
Blood pressure monitoring is recommended as duloxetine can cause increases in some patients 3
Key Differences from Scheduled Medications
- Unlike scheduled medications, duloxetine:
While duloxetine can cause physical dependence with withdrawal symptoms upon abrupt discontinuation, this is distinct from the psychological dependence and abuse potential that characterizes controlled substances 1, 3.